Neurocrine Biosciences (NBIX) Receivables (2010 - 2026)

Neurocrine Biosciences (NBIX) has reported Receivables for 17 consecutive years, with $887.0 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Receivables rose 48.9% year-over-year to $887.0 million; the trailing twelve-month figure through Jun 2026 stood at $887.0 million (up 48.9% YoY), and the FY2025 full-year result was $707.3 million, up 43.32% from the prior year.
• Receivables climbed to $887.0 million in Q2 2026 per NBIX's latest filing, from $768.1 million in the prior quarter.
• Across five years, Receivables topped out at $887.0 million in Q2 2026 and bottomed at $266.5 million in Q1 2022.
• Historically, Receivables has averaged $499.0 million across 5 years, with a median of $465.8 million in 2024.
• The sharpest annual moves came in 2022 and 2024: Receivables jumped 88.97% in 2022, then rose 9.54% in 2024.
• Over 5 years, Receivables stood at $354.7 million in 2022, then advanced by 27.01% to $450.5 million in 2023, then grew by 9.54% to $493.5 million in 2024, then soared by 43.32% to $707.3 million in 2025, then increased by 25.41% to $887.0 million in 2026.
• According to Business Quant data, Receivables over the past three periods registered $887.0 million, $768.1 million, and $707.3 million for Q2 2026, Q1 2026, and Q4 2025 respectively.